Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Sarcopenic patients exhibited elevated hs-CRP, NT-proBNP, ferritin, and uric acid, with lower vitamin D levels.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Association between sarcopenia and the risk of diabetic cardiomyopathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association between sarcopenia and the risk of diabetic cardiomyopathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study
Cohort study · Frontiers in Genetics · 2026
Original publication title
Association between sarcopenia and the risk of diabetic cardiomyopathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study
Copyright © 2026 Liu, Xu, Zhang, Yang and Xiao.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Sarcopenia is an emerging complication of type 2 diabetes mellitus (T2DM) characterized by progressive loss of skeletal muscle mass and function. Diabetic cardiomyopathy (DCM) is a distinct cardiac disease in T2DM patients independent of coronary artery disease and hypertension. Whether sarcopenia independently predicts DCM risk in T2DM patients, and whether shared molecular pathways including systemic inflammation and metabolic dysregulation underlie this association, remains unclear.
Source: BackgroundAbstract: What methods does the paper describe?
This retrospective cohort study enrolled 400 T2DM patients admitted to the First Affiliated Hospital of Chongqing Medical University between February 2022 and February 2026. Sarcopenia was diagnosed using AWGS 2019 criteria as the primary framework, with concurrent evaluation against the updated AWGS 2025 criteria. DCM was diagnosed by Doppler echocardiography in T2DM patients with myocardial dysfunction after excluding other cardiac etiologies, per clinically established criteria (2024 ESC DCM position statement); this echocardiographic approach, while standard practice, does not carry the tissue-characterization precision of cardiac MRI.
Multivariate logistic regression (three sequentially adjusted models), propensity score matching, and prespecified subgroup analyses were performed.
Source: MethodsAbstract: Results
Sarcopenia was identified in 137/400 patients (34.3%) and DCM in 113/400 (28.3%). DCM prevalence was significantly higher in sarcopenic versus non-sarcopenic patients (44.5% vs. 19.8%, p < 0.001). After full adjustment, sarcopenia remained independently associated with DCM risk (adjusted OR = 2.70, 95% CI: 1.72 to 4.24, p < 0.001; AUC-ROC = 0.812). The association was consistent across all subgroups (all p-interaction > 0.05). Sarcopenic patients exhibited elevated hs-CRP, NT-proBNP, ferritin, and uric acid, with lower vitamin D levels.
Source: ResultsAbstract: Conclusion
Sarcopenia is independently associated with significantly elevated DCM risk in T2DM patients; the cross-sectional design precludes definitive causal inference and directionality requires prospective longitudinal confirmation. Shared mechanisms: including systemic inflammation, elevated ferritin and uric acid, and potentially common genetic regulatory pathways (hypothesized on the basis of existing literature): may underlie the muscle: heart dysfunction axis. Routine sarcopenia screening using AWGS 2019 criteria: consistent with the updated AWGS 2025 framework: may facilitate early identification of T2DM patients at elevated DCM risk.
Source: ConclusionAuthors’ abstract
Background
Sarcopenia is an emerging complication of type 2 diabetes mellitus (T2DM) characterized by progressive loss of skeletal muscle mass and function. Diabetic cardiomyopathy (DCM) is a distinct cardiac disease in T2DM patients independent of coronary artery disease and hypertension. Whether sarcopenia independently predicts DCM risk in T2DM patients, and whether shared molecular pathways including systemic inflammation and metabolic dysregulation underlie this association, remains unclear.
Methods
This retrospective cohort study enrolled 400 T2DM patients admitted to the First Affiliated Hospital of Chongqing Medical University between February 2022 and February 2026. Sarcopenia was diagnosed using AWGS 2019 criteria as the primary framework, with concurrent evaluation against the updated AWGS 2025 criteria. DCM was diagnosed by Doppler echocardiography in T2DM patients with myocardial dysfunction after excluding other cardiac etiologies, per clinically established criteria (2024 ESC DCM position statement); this echocardiographic approach, while standard practice, does not carry the tissue-characterization precision of cardiac MRI.
Multivariate logistic regression (three sequentially adjusted models), propensity score matching, and prespecified subgroup analyses were performed.
Results
Sarcopenia was identified in 137/400 patients (34.3%) and DCM in 113/400 (28.3%). DCM prevalence was significantly higher in sarcopenic versus non-sarcopenic patients (44.5% vs. 19.8%, p < 0.001). After full adjustment, sarcopenia remained independently associated with DCM risk (adjusted OR = 2.70, 95% CI: 1.72 to 4.24, p < 0.001; AUC-ROC = 0.812). The association was consistent across all subgroups (all p-interaction > 0.05). Sarcopenic patients exhibited elevated hs-CRP, NT-proBNP, ferritin, and uric acid, with lower vitamin D levels.
Conclusion
Sarcopenia is independently associated with significantly elevated DCM risk in T2DM patients; the cross-sectional design precludes definitive causal inference and directionality requires prospective longitudinal confirmation. Shared mechanisms: including systemic inflammation, elevated ferritin and uric acid, and potentially common genetic regulatory pathways (hypothesized on the basis of existing literature): may underlie the muscle: heart dysfunction axis. Routine sarcopenia screening using AWGS 2019 criteria: consistent with the updated AWGS 2025 framework: may facilitate early identification of T2DM patients at elevated DCM risk.
Publication and source details
Original title: Association between sarcopenia and the risk of diabetic cardiomyopathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study
Xia Liu; Lingjie Xu; Li Zhang; Hailin Yang; Qian Xiao
Frontiers in Genetics · 2026
* Correspondence: Qian Xiao, xiaoqian1956@126.comORCID: Qian Xiao, orcid.org/0000-0001-8855-6561
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:50:18.375668+00:00
DOI: 10.3389/fgene.2026.1892826 · PMC13549478